Professional
Added to YB: 2024-01-09
Pitch date: 2024-01-09
GRFS [bearish]
Grifols, S.A.
+10.89%
current return
Author Info
No bio for this author
Company Info
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Market Cap
EUR 5.4B
Pitch Price
EUR 10.66
Price Target
N/A
Dividend
3.45%
EV/EBITDA
9.52
P/E
14.27
EV/Sales
2.25
Sector
Biotechnology
Category
special_situation
Gotham City Research is short Grifols SA ($GRFS)
GRFS: Gotham City alleges deceptive financials hiding 10-13x leverage (vs reported 6x), questionable consolidation of BPC & Haema without ownership, undisclosed loans, reverse factoring, €124M mystery Immunotek payment. NCIs surged to ~100% of profits. Potentially uninvestable due to CEO/board involvement in dubious transactions.
Read full article (2 min)